



Breast Cancer—Therapeutic Challenges, Research Strategies and Novel Diagnostics

Collection Editor:

Dr. Naiba Nabieva

1. Department of Gynecology and
Obstetrics, Friedrich-Alexander-
Universität Erlangen-Nürnberg,
Erlangen, Germany
2. Novartis Pharma GmbH,
Nürnberg, Germany

Message from the Collection Editor

Dear Colleagues,

Modern therapeutics are changing the treatment landscape of this disease with high speed. In HER2-positive breast cancer patients, for instance, new targeted therapies have reduced mortality rates immensely. However, the role of intrinsic subtypes, certain biomarkers or mutations is still not clear for treatment and surveillance. Novel drugs are often associated with different adverse events compared to conventional therapies. In breast cancer surgery, sometimes, the question remains of whether to escalate or to deescalate. And with regard to diagnostics, in a digitalized world, artificial intelligence, home-based tools and therapy monitoring options are of high importance, especially after conditions seen during the COVID-19 pandemic and supply problems.

Original research articles and reviews demonstrating therapeutic challenges, research strategies and novel diagnostics in breast cancer are appreciated.

We look forward to receiving your contributions.

Dr. Naiba Nabieva

Collection Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI